Precision BioSciences Expands ELIMINATE-B Trial to Europe

Clinical trial application approved in France and Romania to support broader patient enrollment.

Apr. 15, 2026 at 3:39pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the intricate internal structure of the hepatitis B virus, conceptually illustrating the potential of a new gene editing therapy to target and eliminate a critical viral component.A novel gene editing therapy aims to eliminate a key component of the hepatitis B virus, offering hope for new treatment options.Durham Today

Precision BioSciences, Inc., a clinical-stage gene editing company, has announced the expansion of its ELIMINATE-B trial to include sites in France and Romania. This global trial is evaluating PBGENE-HBV, Precision's gene editing therapy designed to eliminate cccDNA, a key component of the hepatitis B virus.

Why it matters

The expansion of the ELIMINATE-B trial to European countries represents an important milestone in the development of PBGENE-HBV, which could potentially offer a new treatment option for the millions of people living with chronic hepatitis B worldwide.

The details

Precision BioSciences has received clinical trial application approvals in France and Romania to include hepatitis sites in those countries as part of the global ELIMINATE-B trial. This will support broader patient enrollment and further the development of PBGENE-HBV, Precision's investigational gene editing therapy designed to eliminate cccDNA, a key component of the hepatitis B virus.

  • The ELIMINATE-B trial is a global clinical study.
  • Precision BioSciences received clinical trial application approvals in France and Romania in April 2026.

The players

Precision BioSciences, Inc.

A clinical-stage gene editing company developing PBGENE-HBV, a therapy designed to eliminate cccDNA, a key component of the hepatitis B virus.

PBGENE-HBV

Precision BioSciences' investigational gene editing therapy designed to eliminate cccDNA, a key component of the hepatitis B virus.

Got photos? Submit your photos here. ›

What’s next

Precision BioSciences plans to continue enrolling patients in the global ELIMINATE-B trial, including the newly added sites in France and Romania.

The takeaway

The expansion of the ELIMINATE-B trial to Europe represents a significant advancement in Precision BioSciences' efforts to develop a novel gene editing therapy that could potentially offer a new treatment option for the millions of people living with chronic hepatitis B.